Benoit Giasson

Benoit Giasson,

Professor, Graduate Co-Coordinator Neuroscience Graduate Program

Department: Department of Neuroscience
Business Phone: (352) 273-9363
Business Email: bgiasson@ufl.edu

Teaching Profile

Courses Taught
2019,2021
GMS6705 Functional Human Neuroanatomy
2019,2021-2024
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2018,2022-2024
GMS7980 Research for Doctoral Dissertation
2018,2022-2024
GMS7979 Advanced Research
2013-2016
GMS6024 Princ Neuroscience 4
2013,2015-2016
GMS6750 Molecular Pathobiology of Neural Disease
2016
GMS7794 Neuroscience Seminar
2013,2015-2021,2021-2024,2024
GMS6029 Brain Journal Club
2022-2024
GMS6701 Functional and Comparative Neuroanatomy for Professionals
2023-2024
GMS6792 Neuroscience Graduate Research Seminar
2023
GMS7795 Special Topics in Neuroscience
2023-2024
GMS6090 Research in Medical Sciences
2024
GMS6910 Supervised Research

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-2992-4234

Publications

2024
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
Molecular Neurodegeneration. 19(1) [DOI] 10.1186/s13024-024-00710-2. [PMID] 38365847.
2023
A C1qTNF3 collagen domain fusion chaperones diverse secreted proteins and anti-Aβ scFvs: Applications for gene therapies.
Molecular therapy. Methods & clinical development. 31 [DOI] 10.1016/j.omtm.2023.101146. [PMID] 38027063.
2023
Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis
Acta Neuropathologica Communications. 11(1) [DOI] 10.1186/s40478-023-01623-9. [PMID] 37482615.
2023
Cellular processing of α-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114.
The Journal of biological chemistry. 299(7) [DOI] 10.1016/j.jbc.2023.104912. [PMID] 37307916.
2023
Complement C1q-dependent engulfment of alpha-synuclein induces ENS-resident macrophage exhaustion and accelerates Parkinson’s-like gut pathology.
bioRxiv : the preprint server for biology. [DOI] 10.1101/2023.10.24.563832. [PMID] 37961460.
2023
Differentiating pathologic tau in chronic traumatic encephalopathy (CTE) from other tauopathies: A potential antibody panel assessment.
Journal of neuropathology and experimental neurology. 82(10):876-879 [DOI] 10.1093/jnen/nlad069. [PMID] 37639632.
2023
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy.
ACS chemical neuroscience. 14(2):235-245 [DOI] 10.1021/acschemneuro.2c00539. [PMID] 36571847.
2023
Human tauopathy strains defined by phosphorylation in R1-R2 repeat domains of tau.
Acta neuropathologica communications. 11(1) [DOI] 10.1186/s40478-023-01664-0. [PMID] 37891635.
2023
Novel Conformation-Dependent Tau Antibodies Are Modulated by Adjacent Phosphorylation Sites.
International journal of molecular sciences. 24(18) [DOI] 10.3390/ijms241813676. [PMID] 37761979.
2023
Polymerization of recombinant tau core fragments in vitro and seeding studies in cultured cells.
Frontiers in neuroscience. 17 [DOI] 10.3389/fnins.2023.1268360. [PMID] 38161790.
2023
Tau Lysine Pseudomethylation Regulates Microtubule Binding and Enhances Prion-like Tau Aggregation.
International journal of molecular sciences. 24(9) [DOI] 10.3390/ijms24098286. [PMID] 37175990.
2023
Tau mutation S356T in the three repeat isoform leads to microtubule dysfunction and promotes prion-like seeded aggregation.
Frontiers in neuroscience. 17 [DOI] 10.3389/fnins.2023.1181804. [PMID] 37304025.
2022
Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation.
Neuropathology and applied neurobiology. 48(2) [DOI] 10.1111/nan.12779. [PMID] 34825397.
2022
Correction to: Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy.
Brain communications. 4(2) [DOI] 10.1093/braincomms/fcac067. [PMID] 35386219.
2022
Corrigendum to “Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy” [Neurosci. Lett. 732 (2020) 1-11/135017].
Neuroscience letters. 783 [DOI] 10.1016/j.neulet.2022.136719. [PMID] 35717861.
2022
Impact of APOE genotype on prion-type propagation of tauopathy.
Acta neuropathologica communications. 10(1) [DOI] 10.1186/s40478-022-01359-y. [PMID] 35440098.
2022
MhcII Regulates Transmission of α-Synuclein-Seeded Pathology in Mice.
International journal of molecular sciences. 23(15) [DOI] 10.3390/ijms23158175. [PMID] 35897751.
2022
Optical pulse labeling studies reveal exogenous seeding slows α-synuclein clearance.
NPJ Parkinson's disease. 8(1) [DOI] 10.1038/s41531-022-00434-4. [PMID] 36535953.
2022
Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice
Communications Biology. 5(1) [DOI] 10.1038/s42003-022-03373-1. [PMID] 35550593.
2022
Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology.
Acta neuropathologica communications. 10(1) [DOI] 10.1186/s40478-022-01394-9. [PMID] 35765058.
2022
Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.
Free neuropathology. 3(9) [DOI] 10.17879/freeneuropathology-2022-3766. [PMID] 35494163.
2022
Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice
Acta Neuropathologica. 143(6):663-685 [DOI] 10.1007/s00401-022-02425-4. [PMID] 35488930.
2021
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Molecular therapy : the journal of the American Society of Gene Therapy. 29(2):859-872 [DOI] 10.1016/j.ymthe.2020.10.007. [PMID] 33128896.
2021
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
Molecular Neurodegeneration. 16(1) [DOI] 10.1186/s13024-021-00486-9. [PMID] 34503546.
2021
Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
Acta Neuropathologica Communications. 9(1) [DOI] 10.1186/s40478-021-01242-2. [PMID] 34454615.
2021
Il-10 signaling reduces survival in mouse models of synucleinopathy.
NPJ Parkinson's disease. 7(1) [DOI] 10.1038/s41531-021-00169-8. [PMID] 33741985.
2021
Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential.
Acta neuropathologica. 142(1):87-115 [DOI] 10.1007/s00401-021-02316-0. [PMID] 33978813.
2021
Novel SOD1 monoclonal antibodies against the electrostatic loop preferentially detect misfolded SOD1 aggregates.
Neuroscience letters. 742 [DOI] 10.1016/j.neulet.2020.135553. [PMID] 33346076.
2021
Pathogenic MAPT mutations Q336H and Q336R have isoform‐dependent differences in aggregation propensity and microtubule dysfunction
Journal of Neurochemistry. 158(2):455-466 [DOI] 10.1111/jnc.15358.
2021
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.
Acta neuropathologica. 141(3):359-381 [DOI] 10.1007/s00401-021-02264-9. [PMID] 33496840.
2021
Precision therapeutic targets for COVID-19
Virology Journal. 18(1) [DOI] 10.1186/s12985-021-01526-y. [PMID] 33781287.
2021
Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy.
Brain communications. 3(2) [DOI] 10.1093/braincomms/fcab104. [PMID] 34136810.
2021
Robust α-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy
Acta Neuropathologica Communications. 9(1) [DOI] 10.1186/s40478-021-01173-y. [PMID] 33941284.
2021
Targeted proteolytic products of τ and α-synuclein in neurodegeneration
Essays in Biochemistry. 65(7):905-912 [DOI] 10.1042/ebc20210028.
2021
Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau-microtubule interactions and inhibits aggregation.
Scientific reports. 11(1) [DOI] 10.1038/s41598-021-96627-7. [PMID] 34426645.
2021
α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability.
NPJ Parkinson's disease. 7(1) [DOI] 10.1038/s41531-021-00210-w. [PMID] 34408150.
2021
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
Molecular Neurodegeneration. 16(1) [DOI] 10.1186/s13024-021-00460-5. [PMID] 34090488.
2020
Carboxy-terminal modification of α-synuclein alters the prion-like propagation of pathology and survival in a mouse model of synucleinopathy
Neuroscience letters. 732
2020
Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy
Neuroscience Letters. 732 [DOI] 10.1016/j.neulet.2020.135017. [PMID] 32371157.
2020
Carboxy‐terminal truncations of mouse α‐synuclein alter aggregation and prion‐like seeding
FEBS Letters. 594(8):1271-1283 [DOI] 10.1002/1873-3468.13728. [PMID] 31912891.
2020
Determinants of seeding and spreading of α-synuclein pathology in the brain
Science Advances. 6(46) [DOI] 10.1126/sciadv.abc2487. [PMID] 33177086.
2020
Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy.
Brain communications. 2(2) [DOI] 10.1093/braincomms/fcaa090. [PMID] 33094280.
2020
Differential patterns of pathologies induced by tau and α-synuclein co-polymer species
Brain communications.
2020
Ex vivo photodynamic studies reveal rapid formation and appreciable turnover of tau aggregates
Nature Neuroscience.
2020
Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases
Journal of Neuropathology and Experimental Neurology. 79(4):407-418 [DOI] 10.1093/jnen/nlaa007. [PMID] 32106300.
2020
Il-10 mediated pathway reduces survival in mouse models of synucleinopathy by altering autophagy and inflammation
Brain Behavior and Immunity.
2020
Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein
Neuroscience Letters. 738 [DOI] 10.1016/j.neulet.2020.135353. [PMID] 32905837.
2020
Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier – phenotypic variability in autosomal dominant Alzheimer’s disease.
Acta neuropathologica communications. 8(1) [DOI] 10.1186/s40478-020-0891-3. [PMID] 32164763.
2020
Spreading of α-synuclein pathology from the pedunculopontine nucleus is governed by connectomics and cell autonomous factors
Science Advances.
2020
Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies
Acta Neuropathologica Communications. 8(1) [DOI] 10.1186/s40478-020-00967-w. [PMID] 32571418.
2020
The emerging role of α-synuclein truncation in aggregation and disease.
The Journal of biological chemistry. 295(30):10224-10244 [DOI] 10.1074/jbc.REV120.011743. [PMID] 32424039.
2020
Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson’s Disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 40(39):7559-7576 [DOI] 10.1523/JNEUROSCI.1468-19.2020. [PMID] 32868457.
2020
α-Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 40(34):6649-6659 [DOI] 10.1523/JNEUROSCI.0189-20.2020. [PMID] 32669353.
2019
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.
The Journal of experimental medicine. 216(11):2479-2491 [DOI] 10.1084/jem.20190430. [PMID] 31467037.
2019
Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
Human molecular genetics. 28(19):3255-3269 [DOI] 10.1093/hmg/ddz151. [PMID] 31261380.
2019
Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils
Acta Neuropathologica Communications. 7(1) [DOI] 10.1186/s40478-019-0733-3. [PMID] 31109378.
2019
Correction to: Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta neuropathologica. 138(4) [DOI] 10.1007/s00401-019-02068-y. [PMID] 31485733.
2019
Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis.
Laboratory investigation; a journal of technical methods and pathology. 99(7):982-992 [DOI] 10.1038/s41374-019-0198-9. [PMID] 30737468.
2019
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta neuropathologica. 138(3):415-441 [DOI] 10.1007/s00401-019-02014-y. [PMID] 31011860.
2019
Exploring the Peripheral Initiation of Parkinson’s Disease in Animal Models.
Neuron. 103(4):547-549 [DOI] 10.1016/j.neuron.2019.07.031. [PMID] 31437447.
2019
Fragile X-associated tremor ataxia syndrome with co-occurrent progressive supranuclear palsy-like neuropathology.
Acta neuropathologica communications. 7(1) [DOI] 10.1186/s40478-019-0818-z. [PMID] 31665069.
2019
Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
The Journal of biological chemistry. 294(48):18488-18503 [DOI] 10.1074/jbc.RA119.010178. [PMID] 31653695.
2019
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Laboratory investigation; a journal of technical methods and pathology. 99(7):912-928 [DOI] 10.1038/s41374-019-0197-x. [PMID] 30742061.
2019
Phosphorylation of serine 305 in tau inhibits aggregation.
Neuroscience letters. 692:187-192 [DOI] 10.1016/j.neulet.2018.11.011. [PMID] 30423399.
2019
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies.
The Journal of experimental medicine. 216(3):539-555 [DOI] 10.1084/jem.20182184. [PMID] 30770411.
2019
Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression
Acta Neuropathologica Communications. 7(1) [DOI] 10.1186/s40478-019-0787-2. [PMID] 31477175.
2019
α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.
Acta neuropathologica. 138(1):1-21 [DOI] 10.1007/s00401-019-01977-2. [PMID] 30798354.
2018
Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces.
Colloids and surfaces. B, Biointerfaces. 166:98-107 [DOI] 10.1016/j.colsurfb.2018.03.011. [PMID] 29550546.
2018
Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.
Acta neuropathologica. 136(6):919-938 [DOI] 10.1007/s00401-018-1895-y. [PMID] 30140941.
2018
Designing antibodies against LRRK2-targeted tau epitopes
PLOS ONE. 13(9) [DOI] 10.1371/journal.pone.0204367. [PMID] 30261006.
2018
Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.
Molecular neurodegeneration. 13(1) [DOI] 10.1186/s13024-018-0253-9. [PMID] 29776378.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry. 293(7):2408-2421 [DOI] 10.1074/jbc.M117.815357. [PMID] 29259137.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry. 293(12) [DOI] 10.1074/jbc.AAC118.002657. [PMID] 29572329.
2018
Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts.
Journal of virology. 92(18) [DOI] 10.1128/JVI.00586-18. [PMID] 29976670.
2018
Locomotor differences in mice expressing wild-type human α-synuclein.
Neurobiology of aging. 65:140-148 [DOI] 10.1016/j.neurobiolaging.2018.01.020. [PMID] 29477894.
2018
Motor defects in mice expressing wild-type human alpha-Synuclein
Neurobiology of Aging. 65:140-148
2018
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.
Neurobiology of disease. 120:98-106 [DOI] 10.1016/j.nbd.2018.09.005. [PMID] 30195075.
2018
Novel monoclonal antibodies targeting the microtubule-binding domain of human tau
PLOS ONE. 13(4) [DOI] 10.1371/journal.pone.0195211. [PMID] 29608591.
2018
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Molecular and cellular neurosciences. 92:17-26 [DOI] 10.1016/j.mcn.2018.05.009. [PMID] 29859891.
2018
Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
The Journal of biological chemistry. 293(49):18914-18932 [DOI] 10.1074/jbc.RA118.005603. [PMID] 30327435.
2018
Prion-like Spreading in Tauopathies.
Biological psychiatry. 83(4):337-346 [DOI] 10.1016/j.biopsych.2017.04.003. [PMID] 28506438.
2018
SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice.
Proceedings of the National Academy of Sciences of the United States of America. 115(8):E1769-E1778 [DOI] 10.1073/pnas.1720739115. [PMID] 29437953.
2018
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease.
The Journal of experimental medicine. 215(9):2247-2264 [DOI] 10.1084/jem.20180484. [PMID] 30158114.
2017
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
PLOS ONE. 12(9) [DOI] 10.1371/journal.pone.0184731. [PMID] 28910367.
2017
Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice.
Human molecular genetics. 26(24):4906-4915 [DOI] 10.1093/hmg/ddx371. [PMID] 29036344.
2017
Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Acta neuropathologica communications. 5(1) [DOI] 10.1186/s40478-017-0458-0. [PMID] 28760159.
2017
Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Molecular genetics and metabolism. 122(4):198-208 [DOI] 10.1016/j.ymgme.2017.11.001. [PMID] 29173981.
2017
Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-016-0142-z. [PMID] 28049533.
2017
Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-017-0182-z. [PMID] 28552073.
2017
Prion-like transmission of α-synuclein pathology in the context of an NFL null background.
Neuroscience letters. 661:114-120 [DOI] 10.1016/j.neulet.2017.09.054. [PMID] 28964772.
2017
Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.
Journal of neurochemistry. 140(4):662-678 [DOI] 10.1111/jnc.13743. [PMID] 27424880.
2017
Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils.
Journal of virology. 91(2) [DOI] 10.1128/JVI.02095-16. [PMID] 27852849.
2017
The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.
PloS one. 12(9) [DOI] 10.1371/journal.pone.0184262. [PMID] 28877262.
2017
The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue.
Nature microbiology. 2(12):1586-1591 [DOI] 10.1038/s41564-017-0057-7. [PMID] 29109476.
2016
Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology.
Acta neuropathologica. 131(1):151-4 [DOI] 10.1007/s00401-015-1505-1. [PMID] 26541429.
2016
Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes.
Acta neuropathologica communications. 4(1) [DOI] 10.1186/s40478-016-0357-9. [PMID] 27503460.
2016
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Acta neuropathologica. 131(1):49-73 [DOI] 10.1007/s00401-015-1485-1. [PMID] 26446103.
2016
Propagation of Aβ, tau and α-synuclein pathology between experimental models and human reality: prions, propagons and propaganda.
Acta neuropathologica. 131(1):1-3 [DOI] 10.1007/s00401-015-1517-x. [PMID] 26715564.
2015
Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.
Journal of neurochemistry. 135(5):958-74 [DOI] 10.1111/jnc.13292. [PMID] 26303407.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica. 130(2):303-5 [DOI] 10.1007/s00401-015-1444-x. [PMID] 25982997.
2015
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Journal of neuroscience research. 93(10):1567-80 [DOI] 10.1002/jnr.23614. [PMID] 26123245.
2015
Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice.
Molecular neurodegeneration. 10 [DOI] 10.1186/s13024-015-0029-4. [PMID] 26223783.
2015
The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture.
Neuroscience letters. 597:43-8 [DOI] 10.1016/j.neulet.2015.04.022. [PMID] 25892596.
2014
A cellular system that eliminates misfolded proteins through sequential SUMOylation and ubiquination
Science.
2014
Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.
Acta neuropathologica. 127(5):645-65 [PMID] 24659240.
2014
Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Brain : a journal of neurology. 137(Pt 12):3235-47 [DOI] 10.1093/brain/awu291. [PMID] 25351739.
2014
Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 34(37):12368-78 [DOI] 10.1523/JNEUROSCI.2102-14.2014. [PMID] 25209277.
2014
Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Journal of neurochemistry. 131(6):859-67 [DOI] 10.1111/jnc.12806. [PMID] 24984882.
2014
Evidence of native α-synuclein conformers in the human brain.
The Journal of biological chemistry. 289(11):7929-34 [DOI] 10.1074/jbc.C113.538249. [PMID] 24474688.
2014
Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice.
Proceedings of the National Academy of Sciences of the United States of America. 111(29):10732-7 [DOI] 10.1073/pnas.1321785111. [PMID] 25002524.
2014
Transgenic mice expressing S129 phosphorylation mutations in alpha-synuclein
Neuroscience letters. 563:96-100 [DOI] 10.1016/j.neulet.2014.01.033. [PMID] 24486885.
2013
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.
JAMA neurology. 70(6):727-35 [DOI] 10.1001/jamaneurol.2013.1925. [PMID] 23588557.
2013
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Human molecular genetics. 22(10):2067-82 [DOI] 10.1093/hmg/ddt057. [PMID] 23393156.
2013
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration.
The Journal of clinical investigation. 123(12):5389-400 [DOI] 10.1172/JCI70317. [PMID] 24270424.
2013
Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-17. [PMID] 23714769.
2013
Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein.
Acta neuropathologica communications. 1 [DOI] 10.1186/2051-5960-1-38. [PMID] 24252149.
2013
LRRK2 Phosphorylates novel tau epitopes and promotes tauopathy
The Journal of Neuroscience.
2013
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.
Acta neuropathologica. 126(6):809-27 [DOI] 10.1007/s00401-013-1188-4. [PMID] 24113872.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica. 126(1):39-50 [DOI] 10.1007/s00401-013-1123-8. [PMID] 23666556.
2013
Thinking laterally about neurodegenerative proteinopathies.
The Journal of clinical investigation. 123(5):1847-55 [DOI] 10.1172/JCI66029. [PMID] 23635781.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.
Brain research. 1524:62-73 [DOI] 10.1016/j.brainres.2013.06.006. [PMID] 23774650.
2012
Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.
Journal of neuroscience research. 90(12):2306-16 [DOI] 10.1002/jnr.23112. [PMID] 22847264.
2012
Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?
Alzheimer's research & therapy. 4(6) [DOI] 10.1186/alzrt151. [PMID] 23245350.
2012
Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice.
Neuroscience letters. 507(2):137-42 [DOI] 10.1016/j.neulet.2011.12.005. [PMID] 22188655.
2011
Characterization of kinases involved in the phosphorylation of aggregated α-synuclein.
Journal of neuroscience research. 89(2):231-47 [DOI] 10.1002/jnr.22537. [PMID] 21162130.
2011
E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.
The Journal of biological chemistry. 286(40):35104-18 [DOI] 10.1074/jbc.M111.247965. [PMID] 21846727.
2011
Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 31(21):7604-18 [DOI] 10.1523/JNEUROSCI.0297-11.2011. [PMID] 21613474.
2011
α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
Neurotoxicology. 32(5):622-9 [DOI] 10.1016/j.neuro.2011.01.003. [PMID] 21238487.
2010
A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation.
Journal of neurochemistry. 113(2):374-88 [DOI] 10.1111/j.1471-4159.2010.06592.x. [PMID] 20132485.
2010
Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(9):3409-18 [DOI] 10.1523/JNEUROSCI.4977-09.2010. [PMID] 20203200.
2010
DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.
Human molecular genetics. 19(8):1425-37 [DOI] 10.1093/hmg/ddq017. [PMID] 20089532.
2010
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.
Proceedings of the National Academy of Sciences of the United States of America. 107(21):9747-52 [DOI] 10.1073/pnas.0911175107. [PMID] 20457924.
2010
Effects of divalent cations on the kinase activity of wild-type and disease causing mutations of leucine-rich repeat kinase 2
Journal of Neurochemistry. 115:36-46
2010
Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.
Human molecular genetics. 19(9):1633-50 [DOI] 10.1093/hmg/ddq038. [PMID] 20106867.
2010
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.
Acta neuropathologica. 120(5):641-9 [DOI] 10.1007/s00401-010-0741-7. [PMID] 20838799.
2010
Identification and characterization of a novel endogenous murine parkin mutation.
Journal of neurochemistry. 113(2):402-17 [DOI] 10.1111/j.1471-4159.2010.06605.x. [PMID] 20089136.
2010
L10p and P158DEL DJ-1 mutations cause protein instability, aggregation, and dimerization impairments.
Journal of neuroscience research. 88(14):3111-24 [DOI] 10.1002/jnr.22477. [PMID] 20806408.
2010
PARK7/DJ-1 is important for mitochondrial function and interacts with Parkin/PINK1
Proceedings of the National Academy of Sciences. 25:9747-9752
2010
Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation.
Biochemical and biophysical research communications. 391(3):1415-20 [DOI] 10.1016/j.bbrc.2009.12.079. [PMID] 20026050.
2010
The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
Journal of neurochemistry. 115(1):36-46 [DOI] 10.1111/j.1471-4159.2010.06894.x. [PMID] 20626563.
2009
Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization.
Biochemistry. 48(40):9427-36 [DOI] 10.1021/bi900539p. [PMID] 19722699.
2009
Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.
Movement disorders : official journal of the Movement Disorder Society. 24(1):32-9 [DOI] 10.1002/mds.22096. [PMID] 19006185.
2009
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.
Biochemical and biophysical research communications. 378(3):473-7 [DOI] 10.1016/j.bbrc.2008.11.048. [PMID] 19027715.
2009
Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.
Journal of neuropathology and experimental neurology. 68(7):785-96 [DOI] 10.1097/NEN.0b013e3181aaf4fd. [PMID] 19535993.
2009
Molecular mechanisms of alpha-synuclein neurodegeneration.
Biochimica et biophysica acta. 1792(7):616-24 [DOI] 10.1016/j.bbadis.2008.09.013. [PMID] 18955133.
2008
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia.
Neurobiology of aging. 29(5):739-52 [PMID] 17166628.
2008
Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions.
Acta neuropathologica. 116(1):37-46 [DOI] 10.1007/s00401-008-0375-1. [PMID] 18414880.
2008
Mutations in LRRK2 as a cause of Parkinson’s disease.
Neuro-Signals. 16(1):99-105 [PMID] 18097165.
2008
Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid.
The Journal of biological chemistry. 283(1):6-16 [DOI] 10.1074/jbc.M706124200. [PMID] 17921521.
2008
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
Journal of neuropathology and experimental neurology. 67(5):402-16 [DOI] 10.1097/NEN.0b013e31816fc995. [PMID] 18451726.
2008
The E163K DJ-1 mutant shows specific antioxidant deficiency.
Brain research. 1239:1-11 [DOI] 10.1016/j.brainres.2008.09.009. [PMID] 18822273.
2007
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.
The American journal of pathology. 170(2):658-66 [PMID] 17255333.
2007
Role of mitochondrial dysfunction in Parkinson’s disease: Implications for treatment.
Drugs & aging. 24(2):95-105 [PMID] 17313198.
2006
Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 20(12):2000-8 [PMID] 17012252.
2006
Biochemical and pathological characterization of Lrrk2.
Annals of neurology. 59(2):315-22 [PMID] 16437584.
2006
Common threads in neurodegenerative disorders of aging
Alzheimers & Dementia. 2:322-326
2006
Common threads in neurodegenerative disorders of aging.
Alzheimer's & dementia : the journal of the Alzheimer's Association. 2(4):322-6 [DOI] 10.1016/j.jalz.2006.08.008. [PMID] 19595906.
2006
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.
The American journal of pathology. 168(3):947-61 [PMID] 16507910.
2006
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(39):10068-78 [PMID] 17005870.
2006
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.
Neurology. 67(5):908-10 [PMID] 16790605.
2005
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
The Journal of biological chemistry. 280(24):22670-8 [PMID] 15840579.
2005
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
Biochemistry. 44(21):7818-29 [PMID] 15909996.
2005
DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein.
Journal of neurochemistry. 93(6):1524-32 [PMID] 15935068.
2005
Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration.
Neuron. 45(6):847-59 [PMID] 15797547.
2005
Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.
The Journal of biological chemistry. 280(22):21212-9 [PMID] 15817478.
2005
Role of oxidative damage in protein aggregation associated with Parkinson’s disease and related disorders.
Antioxidants & redox signaling. 7(5-6):672-84 [PMID] 15890012.
2005
Snaring the function of alpha-synuclein.
Cell. 123(3):359-61 [PMID] 16269324.
2005
The E46K mutation in alpha-synuclein increases amyloid fibril formation.
The Journal of biological chemistry. 280(9):7800-7 [PMID] 15632170.
2004
Alpha-synuclein: normal function and role in neurodegenerative diseases.
Current topics in developmental biology. 60:17-54 [PMID] 15094295.
2004
Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons.
The Journal of cell biology. 165(3):335-46 [PMID] 15123735.
2004
Fibrillization of alpha-synuclein and tau in familial Parkinson’s disease caused by the A53T alpha-synuclein mutation.
Experimental neurology. 187(2):279-88 [PMID] 15144854.
2004
Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation.
The Journal of biological chemistry. 279(46):47746-53 [PMID] 15364911.
2004
Mitochondrial injury: a hot spot for parkinsonism and Parkinson’s disease?
Science of aging knowledge environment : SAGE KE. 2004(48) [PMID] 15576821.
2004
More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Trends in neurosciences. 27(3):129-34 [PMID] 15036877.
2003
A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114.
Journal of neurochemistry. 86(6):1359-68 [PMID] 12950445.
2003
A novel assay to monitor amyloidogenicity in solution using the fluorescent dye K114
Journal of Neurochemistry. 86:1359-1368
2003
Age-dependent synuclein pathology following traumatic brain injury in mice.
Experimental neurology. 184(1):214-24 [PMID] 14637093.
2003
Are ubiquitination pathways central to Parkinson’s disease?
Cell. 114(1):1-8 [PMID] 12859888.
2003
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
Journal of neurochemistry. 86(4):836-47 [PMID] 12887682.
2003
Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications.
The Journal of biological chemistry. 278(29):27230-40 [PMID] 12857790.
2003
Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas.
Acta neuropathologica. 106(2):167-75 [PMID] 12783249.
2003
Initiation and synergistic fibrillization of tau and alpha-synuclein.
Science (New York, N.Y.). 300(5619):636-40 [PMID] 12714745.
2003
Interactions of amyloidogenic proteins.
Neuromolecular medicine. 4(1-2):49-58 [PMID] 14528052.
2003
Nitration of tau protein is linked to neurodegeneration in tauopathies.
The American journal of pathology. 163(3):1021-31 [PMID] 12937143.
2003
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
The Journal of biological chemistry. 278(48):48120-8 [PMID] 12972409.
2003
Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
Biochemistry. 42(28):8530-40 [PMID] 12859200.
2003
Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy.
Acta neuropathologica. 106(3):243-50 [PMID] 12811584.
2003
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
The American journal of pathology. 163(1):91-100 [PMID] 12819014.
2002
Alpha-Synuclein becomes proteinase K-resistant and hyperphosphorylated in aged transgenic mice and in Lewy body disease patients
. 110:1429-1439
2002
AMPA receptor-mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase 3.
Journal of neurochemistry. 82(2):398-409 [PMID] 12124441.
2002
Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways.
The Journal of biological chemistry. 277(38):35050-60 [PMID] 12121974.
2002
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.
Annals of neurology. 52(2):205-10 [PMID] 12210791.
2002
The environmental toxin arsenite induces tau hyperphosphorylation.
Biochemistry. 41(51):15376-87 [PMID] 12484777.
2001
A fluorescent Congo red derived ligand that binds A beta deposits in transgenic mouse brains, in vivo labels diverse lesions formed by beta-pleated sheet structures in postmortem human neurodegenerative disease brains
The American Journal Of Pathology. 159:937-943
2001
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.
The Journal of biological chemistry. 276(4):2380-6 [PMID] 11060312.
2001
Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons.
Experimental neurology. 172(2):354-62 [PMID] 11716559.
2001
The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains.
The American journal of pathology. 159(3):937-43 [PMID] 11549586.
2000
A new link between pesticides and Parkinson’s disease.
Nature neuroscience. 3(12):1227-8 [PMID] 11100135.
2000
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson’s disease.
Journal of neuroscience research. 59(4):528-33 [PMID] 10679792.
2000
Chaperone-like activity of synucleins.
FEBS letters. 474(1):116-9 [PMID] 10828462.
2000
Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
The Journal of biological chemistry. 275(24):18344-9 [PMID] 10747881.
2000
Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy.
Journal of neuropathology and experimental neurology. 59(9):830-41 [PMID] 11005264.
2000
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.
The American journal of pathology. 157(2):361-8 [PMID] 10934140.
2000
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
Science (New York, N.Y.). 290(5493):985-9 [PMID] 11062131.
2000
Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary.
Cancer. 88(9):2154-63 [PMID] 10813729.
2000
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.
The American journal of pathology. 157(5):1439-45 [PMID] 11073803.
1999
Activation of stress-activated protein kinases correlates with neurite outgrowth induced by protease inhibition in PC12 cells.
Journal of neurochemistry. 72(3):1081-7 [PMID] 10037479.
1999
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.
The Journal of biological chemistry. 274(12):7619-22 [PMID] 10075647.
1999
Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis.
Journal of neurochemistry. 72(2):693-9 [PMID] 9930742.
1998
Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter.
Nucleic acids research. 26(2):486-9 [PMID] 9421504.
1998
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.
Annals of neurology. 44(3):415-22 [PMID] 9749615.
1998
Intermediate filament disassembly in cultured dorsal root ganglion neurons is associated with amino-terminal head domain phosphorylation of specific subunits.
Journal of neurochemistry. 70(5):1869-75 [PMID] 9572270.
1998
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes.
The American journal of pathology. 153(5):1365-70 [PMID] 9811326.
1997
Developmentally regulated stabilization of neuronal intermediate filaments in rat cerebral cortex.
Neuroscience letters. 229(2):77-80 [PMID] 9223595.
1997
Developmentally regulated stabilization of neuronal intermediate filaments in rat cerebral cortex.
. 229:77-80
1997
Okadaic acid reversibly inhibits neurite outgrowth in embryonic dorsal root ganglion neurons.
Journal of neurobiology. 32(2):193-201 [PMID] 9032661.
1997
Study of proline-directed protein kinases involved in phosphorylation of the heavy neurofilament subunit.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 17(24):9466-72 [PMID] 9391002.
1996
Aberrant stress-induced phosphorylation of perikaryal neurofilaments.
The Journal of biological chemistry. 271(48):30404-9 [PMID] 8940004.
1996
Activation of cyclic AMP-dependent protein kinase in okadaic acid-treated neurons potentiates neurofilament fragmentation and stimulates phosphorylation of Ser2 in the low-molecular-mass neurofilament subunit.
Journal of neurochemistry. 66(3):1207-13 [PMID] 8769885.
1995
Increased phosphorylation of neurofilament subunits in PC12 cells and rat dorsal root ganglion neurons treated with N-Acetyl-Leu-Leu-norleucinal.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 13(7):753-8 [PMID] 8787865.

Grants

Jul 2023 ACTIVE
The interactions between myenteric macrophages and enteric neurons shape development and spread of enteric synucleinopathy
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
May 2023 ACTIVE
Investigating the role of myenteric macrophages in enteric synucleinopathy
Role: Other
Funding: NATL INST OF HLTH NINDS
Mar 2023 ACTIVE
Molecular mechanisms of alpha-synuclein induction and spread of pathobiology
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2022 ACTIVE
Deciphering tau phosphorylation and Abeta/tau strain interactions in Alzheimers pathogenesis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Jun 2022 ACTIVE
Protection of dopaminergic neuronal function
Role: Other
Funding: PARKINSONS FOU
May 2021 ACTIVE
Cognitive and Affective Network Dysfunction and Neuromodulation in Aging and Synucleinopathy
Role: Other
Funding: NATL INST OF HLTH NIA
Mar 2021 ACTIVE
Investigating Mechanisms of Neurodegeneration in Transgenic Mouse Models of Tauopathies
Role: Other
Funding: NATL INST OF HLTH NIA
Jun 2020 ACTIVE
1Florida Alzheimers Disease Research Center
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2019 – Aug 2022
Adoptive Cell Therapies and Translational Neuroimaging in Synucleinopathy: Implications for Dementia with Lewy Body and Parkinson's Disease
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
May 2019 – May 2022
Towards Understanding the Initiating Role of Truncated Alpha-Synuclein in Neurodegeneration
Role: Other
Funding: NATL INST OF HLTH NIA
Mar 2019 – Feb 2021
Mechanisms of abnormal neuronal tau accumulation, interactions with amyloid-beta and pathological sequelae
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2019 – Jan 2024
Metabolic Interventions for Enhancing Cognitive Resilience in Aging and Alzheimers Disease.
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018 ACTIVE
Prion and non-prion induction mechanisms of alpha-synuclein pathology
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2018 – Aug 2023
Decision making and basolateral amygdala dysfunction in aging
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Jun 2018 – Aug 2023
APOE as a modifier of prion-like spread in dementia
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Mar 2018 – Feb 2021
Interactions of Perirhinal Tau Pathology and Aging in Cognitive Dysfunction
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – May 2018
APOE as a modifier of prion-like spread in dementia
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – Nov 2020
Immune modulation and CNS pathology following exogenous a-synuclein challenge
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2017 – Mar 2021
Pathological spread and outcomes of alpha-synuclein mutants
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Feb 2017 – Dec 2017
Misc Donors Account
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Feb 2017 – Sep 2019
Understanding the molecular mechanisms of seeding and transmission of wild type and mutant tau
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Nov 2016 – Nov 2020
Comparative prionoid and strain properties of tau and synuclein
Role: Co-Investigator
Funding: ALZHEIMERS ASSO
Aug 2015 – May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Aug 2015 – Jul 2018
Somatic inactivation of the SNCA locus: a new approach to the understanding and treatment of Parkinson's Disease
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Sep 2014 – Jan 2022
Mechanisms of Aggregated Alpha-Synuclein Induction and Progression
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
May 2014 – Aug 2016
Studies of prion-like peripheral to CNS transmission of alpha-synuclein pathology mouse models
Role: Principal Investigator
Funding: NATL PARKINSON FOU
Jul 2013 – Jun 2023
Studies of a-Synuclein and Tau Pathobiologies
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Jul 2013 – Jun 2018
Biological and Pathological Interactions between Tau and LRRK2
Role: Project Manager
Funding: NATL INST OF HLTH NINDS

Contact Details

Phones:
Business:
(352) 273-9363
Emails:
Business:
bgiasson@ufl.edu
Addresses:
Business Mailing:
PO BOX 100159
1275 CENTER DRIVE, BMS BUILDING J-483
GAINESVILLE FL 326100159